Jones Financial Companies
MBRX icon

Jones Financial Companies’s Moleculin Biotech MBRX Stock Holding History

Jones Financial Companies’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18K Buy
+360
New +$919 ﹤0.01% 4568

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jones Financial Companies's MBRX Position: Q2 2026 in Review

Jones Financial Companies opened a new position in Moleculin Biotech (MBRX) in Q2 2026: 360 shares worth $1.18K. The stake represents ﹤0.01% of the portfolio and ranks #4568 among its holdings.

17 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Jones Financial Companies held 360 shares of Moleculin Biotech worth $1.18K as of Q2 2026.
  • Moleculin Biotech was a new Jones Financial Companies position in Q2 2026.
  • Moleculin Biotech made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4568 holding.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.